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Abstract: Clinical presentations of atherothrombotic vascular disease, such as acute coronary 
syndromes, ischemic stroke or transient ischemic attack, and symptomatic peripheral arterial 
disease, are major causes of morbidity and mortality worldwide. Platelet activation and aggrega-
tion play a seminal role in the arterial thrombus formation that precipitates acute manifestations 
of atherothrombotic disease. As a result, antiplatelet therapy has become the cornerstone of 
therapy for the prevention and treatment of atherothrombotic disease. Dual antiplatelet therapy 
with aspirin and a P2Y12 adenosine diphosphate (ADP) receptor inhibitor, such as clopidogrel 
or prasugrel, is the current standard-of-care antiplatelet therapy in patients with acute coronary 
syndromes managed with an early invasive strategy. However, these agents are associated with 
several important clinical limitations, including significant residual risk for ischemic events, 
bleeding risk, and variability in the degree of platelet inhibition. The residual risk can be attributed 
to the fact that aspirin and P2Y12 inhibitors block only the thromboxane A2 and ADP platelet 
activation pathways but do not affect the other pathways that lead to thrombosis, such as the 
protease-activated receptor-1 pathway stimulated by thrombin, the most potent platelet agonist. 
Bleeding risk associated with aspirin and P2Y12 inhibitors can be explained by their inhibitory 
effects on the thromboxane A2 and ADP pathways, which are critical for protective hemostasis. 
Interpatient variability in the degree of platelet inhibition in response to antiplatelet therapy 
may have a genetic component and contribute to poor clinical outcomes. These considerations 
underscore the clinical need for therapies with a novel mechanism of action that may reduce 
ischemic events without increasing the bleeding risk.
Keywords: acute coronary syndromes, antiplatelet therapy, ADP, thromboxane A2, 
PAR-1, bleeding
Introduction
Platelets play a key role in preventing blood loss in response to injury, but they are 
also critical for the formation of pathogenic thrombi responsible for the acute clini-
cal manifestations of atherothrombotic disease. These events include acute coronary 
syndromes (ACS: unstable angina [UA], non-ST-elevation [NSTE] myocardial infarc-
tion [MI], and ST-elevation MI [STEMI]), ischemic stroke/transient ischemic attack 
(TIA), and symptomatic peripheral artery disease (PAD), which are major causes of 
morbidity and mortality worldwide.1,2
The crucial step in both protective hemostasis and pathological thrombosis is plate-
let activation, which can occur via multiple pathways. These pathways are activated by 
binding of specific agonists, such as thromboxane A2 (TxA2), adenosine diphosphate 
(ADP), and thrombin, to their corresponding receptors on the platelet surface.3–5 
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Additional factors that contribute to platelet activation 
include epinephrine, prostaglandin E2, serotonin, and various 
chemokines. Although these factors may directly activate 
platelets, this effect is very weak, and they predominantly 
serve to potentiate platelet activation induced by other 
stimuli.5 Under physiological conditions, ligand-stimulated 
activation of platelets is counteracted by a number of 
endothelial-derived factors that prevent uncontrolled plate-
let aggregation, including nitric oxide and prostacyclin, 
which raise the intracellular levels of cyclic nucleotides 
(cyclic guanosine monophosphate and cyclic adenosine 
monophosphate). In addition, the nucleoside adenosine, 
which is released as a result of cell damage or by endothelial 
ectonucleotidase CD39-mediated conversion of ADP, also 
inhibits platelet activation via activation of the Gs-coupled 
adenosine A2A receptor.5,6
Current oral antiplatelet agents target the TxA2 (aspirin) 
and ADP (P2Y12 inhibitors, such as clopidogrel, ticlopidine, 
and prasugrel) platelet activation pathways4 and have been 
demonstrated to significantly reduce the incidence of isch-
emic events in patients with atherothrombotic disease.7–10 
The well-documented efficacy of aspirin and clopidogrel 
has been recognized by the American College of Cardiol-
ogy/American Heart Association guidelines,11–14 and dual 
antiplatelet therapy with aspirin and a P2Y12 inhibitor has 
emerged as the standard of care in the management of 
patients with ACS.
However, despite the established benefits of aspirin and 
ADP receptor inhibitors, these agents are associated with 
important clinical limitations, including a high residual risk 
for ischemic events, elevated bleeding risk, and variable 
inhibition of platelet aggregation. These considerations 
underscore the need for novel therapies that can further 
reduce the risk for ischemic events without exposing patients 
to increased risk of bleeding. The aims of this review are to 
provide a pathophysiological rationale for the clinical use of 
antiplatelet agents, to summarize the benefits and limitations 
of current oral antiplatelet therapies, and to discuss novel 
approaches to oral antiplatelet therapy.
Pathogenesis of atherothrombosis  
and rationale for antiplatelet therapy
Atherosclerosis develops within the intima of large- and 
medium-sized arteries and can be triggered by behavioral, 
environmental, biochemical, or genetic factors.15 The earli-
est pathological feature of atherothrombosis is endothelial 
dysfunction,15–18 which is exemplified by endothelial cell 
expression of vascular cell adhesion molecules and increased 
endothelial permeability to lipoproteins, leukocytes, and 
other inflammatory mediators, favoring plaque growth.15,17,19 
The composition of plaques is the major determinant of their 
susceptibility to rupture/erosion, which ultimately serves 
as a trigger that precipitates an acute thrombotic event.17,20 
The unstable, rupture-prone lesions typically comprise a 
large core of extracellular lipid, a dense accumulation of 
macrophages, reduced numbers of vascular smooth muscle 
cells, and a thin, fibrous cap. Plaque rupture usually occurs 
in the areas where the cap is the thinnest and most heavily 
infiltrated with inflammatory cells.17,21 Rupture or erosion of 
these lesions exposes circulating blood to a highly thrombo-
genic environment that causes inappropriate platelet activa-
tion, ultimately leading to occlusion of the arterial lumen 
by platelet-rich thrombi. These thrombi obstruct blood flow 
and oxygen supply (ischemia) in the affected arteries and are 
responsible for the clinical manifestations of atherothrom-
botic diseases.15
Platelets play a critical role in atherothrombotic disease, 
as they are the primary constituent of occlusive thrombi at the 
sites of ruptured/eroded plaques. Formation of an occlusive 
thrombus proceeds in three stages: (1) the initiation phase, 
(2) the extension phase, and (3) the perpetuation phase.3–6,22 
In the initiation phase, platelets roll, adhere, and spread on the 
subendothelial collagen matrix to form a platelet monolayer. 
The initial adhesion of platelets to subendothelium is medi-
ated primarily by direct interaction between the glycoprotein 
(GP) Ib/V/IX receptor complex on the platelet surface and 
von Willebrand factor. Independent and direct interaction 
between exposed subendothelial collagen with platelet 
receptors GP VI and GP Ia stimulates the release of platelet 
agonists ADP and TxA2 from the adherent platelets, as well as 
activation of GP IIb/IIIa, the high-affinity fibrinogen receptor 
that mediates firm and stable adhesion of platelets to the ves-
sel wall, platelet-platelet crosslinking, and contact-dependent 
signalling within platelet aggregates.3,5,6,22
Platelet activation in the extension phase is crucial for 
both hemostasis and thrombosis and can be induced by mul-
tiple agonists, including ADP, TxA2, and thrombin.6 Local 
release of ADP and TxA2 stimulated by collagen promotes 
the recruitment of circulating platelets into the growing, 
stable hemostatic plug. Thrombin-mediated cleavage of 
fibrinogen into fibrin can also contribute to the formation 
of hemostatic plugs. ADP and TxA2 activate platelets via 
binding to distinct receptors on the platelet surface (ADP 
binds to P2Y1 and P2Y12 receptors, and TxA2 binds the 
endoperoxide PGG2-PGH2 [TP] receptors TPα and TPβ).3 
ADP- and TxA2-induced activation of their corresponding 
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receptors results in reduced intracellular cyclic adenosine 
monophosphate levels and full activation of GP IIb/IIIa.5 
ADP and TxA2 can also potentiate platelet activation 
induced by other ligands.5 Thrombin activates platelets 
primarily by binding protease-activated receptor (PAR)-1 
on the human platelet surface, cleaving the receptor, and 
exposing a tethered ligand, which binds and activates the 
receptor (Figure 1A).3,23,24 Thrombin is the most potent 
platelet agonist, as it can stimulate platelet activation via the 
PAR-1 pathway at very low concentrations ( Figure 1B) that 
are several orders of magnitude lower than those required 
for the activation of the coagulation cascade.25,26 Human 
platelets also express a secondary receptor for thrombin, 
PAR-4, which requires higher concentrations of thrombin 
for activation than does PAR-1.23
The perpetuation phase of thrombus formation is medi-
ated by the cell-to-cell contact-dependent mechanisms 
that lead to changes in platelet morphology, expression of 
procoagulant and proinflammatory molecules, and platelet 
aggregation. Thrombus in acute atherothrombotic events 
(ACS, ischemic stroke, or symptomatic PAD) can be either 
partially or completely occlusive – the former composed 
primarily of platelet aggregates, and the latter composed of 
a platelet aggregate core and a superimposed fibrin-rich clot 
generated by the coagulation cascade.
Platelets are therefore a critical mediator of thrombosis 
and acute ischemic events, but they are also essential for nor-
mal hemostasis. Because the activation of multiple platelet 
activation pathways is the primary mechanism of thrombosis 
and ischemic events, their comprehensive inhibition repre-
sents an attractive therapeutic approach in atherothrombotic 
disease. However, the potential clinical benefits of targeting 
various platelet activation pathways should be carefully 
weighed against the likelihood of increased bleeding, as 
both the TxA2 and ADP platelet activation pathways are also 
required for hemostasis.
Overview of oral antiplatelet therapy
The current standard-of-care oral antiplatelet therapy for 
patients with ACS (UA, NSTEMI, and STEMI) and follow-
ing placement of a stent is the combination of aspirin and 
the thienopyridine P2Y12 inhibitor clopidogrel or prasugrel, 
which is recommended for up to 1 year.11,12,14 Prasugrel is a 
novel oral thienopyridine P2Y12 inhibitor that has recently 
been approved in Europe and the US. The results of large 
clinical trials with high-dose clopidogrel and a novel, oral 
nonthienopyridine P2Y12 inhibitor ticagrelor (AZD6140) 
have been recently reported.
Figure  1B  Platelet  activation  by  the  PAR-1  pathway  stimulated  by  binding  of 
thrombin.
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Figure 1A Mechanism of protease-activated receptor (PAR)-1 activation by thrombin. 
PAR-1  is  a  G  protein-coupled  receptor  for  thrombin.  Thrombin  recognizes  the 
N-terminal exodomain of PAR-1 by interacting with a hirudin-like domain. Thrombin 
cleaves the peptide bond between receptor residues arginine 41 and serine 42. This 
serves to unmask a new amino terminus that functions as a tethered ligand, which binds 
intramolecularly with the body of the receptor to effect transmembrane signalling. 
Reproduced with permission. Copyright © 2004. American Physiological Society. 
Ossovskaya  VS,  Bunnett  Nw.  Protease-activated  receptors:  contribution  to 
physiology and disease. Physiol Rev. 2004;84(2):579–621.24
Aspirin
Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1), 
reducing the synthesis of TxA2, an important platelet 
  activator.27 Numerous trials have documented the benefits 
of aspirin in patients with ACS8,28 and in those undergoing 
percutaneous coronary intervention (PCI),29,30 as well as in 
secondary prevention.8 A study of 1266 men with UA showed 
that daily aspirin significantly decreased the risk of death 
or MI;28 in other studies, pretreatment or long-term therapy 
with aspirin was shown to reduce the risk of thrombotic 
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complications in patients undergoing PCI.29,30 A number of 
meta-analyses have demonstrated that aspirin significantly 
reduces the risk for vascular events in high-risk patients with 
a history of MI, stroke, TIA, or angina, as well as in patients 
without prior history of atherothrombotic disease.7,8,31 A recent 
meta-analysis evaluated the benefit of aspirin in primary 
prevention of cardiovascular disease.31 Although a significant 
reduction in occlusive events was observed in patients treated 
with aspirin (12% proportional risk reduction, P = 0.0001), 
there was a limited clinical benefit in this setting when the 
absolute increase in bleeding risk was taken into account. 
Additionally, treatment with aspirin was not associated 
with a significant reduction in overall vascular mortality in 
this setting (P = 0.70).31
Clopidogrel
Clopidogrel prevents ADP-induced platelet activation and 
aggregation by irreversibly inhibiting the platelet ADP 
receptor P2Y12.32 The clinical efficacy of clopidogrel has 
been demonstrated both as an add-on to aspirin in the set-
tings of NSTE ACS,10 PCI,33,34 and STEMI,35,36 and as single 
antiplatelet therapy for secondary prevention.37
In the CURE (Clopidogrel in Unstable Angina to Prevent 
Recurrent Events) trial, a total of 12,562 patients with NSTE 
ACS treated with aspirin (75–325 mg daily) were randomly 
assigned to receive clopidogrel (loading dose of 300 mg, fol-
lowed by 75 mg daily) or placebo for 3–12 months.10 Dual 
antiplatelet therapy with clopidogrel and aspirin significantly 
reduced the primary endpoint of death from cardiovascular 
causes, nonfatal MI, or stroke versus aspirin alone (9.3% vs 
11.4%, respectively; P , 0.001), but it was also associated 
with a significantly higher major bleeding rate compared 
with aspirin alone (3.7% vs 2.7%, respectively; relative 
risk 1.38, P = 0.001).10 In patients who underwent PCI 
(PCI-CURE), those who received clopidogrel and aspirin 
had a significantly lower rate of the primary endpoint of 
cardiovascular death, MI, or urgent target-vessel revascu-
larization within 30 days of PCI (4.5% vs 6.4% with aspirin 
alone, P = 0.03).33
The CREDO (Clopidogrel for the Reduction of Events 
During Observation) trial evaluated the benefit of 12-month 
treatment with clopidogrel (75 mg/day) after PCI and the 
effect of a preprocedural clopidogrel loading dose (300 mg) 
in addition to aspirin therapy (81–325 mg) in patients under-
going elective PCI.34 Dual antiplatelet therapy was associated 
with a significant 27% relative reduction in the composite 
endpoint of death, MI, or stroke (P = 0.02) at 1 year versus 
aspirin alone, whereas no significant benefit of the 300 mg 
loading dose of clopidogrel was apparent at 28 days.34 
There was a nonsignificant increase in rate of major bleed-
ing in the clopidogrel plus aspirin group (8.8% vs 6.7% with 
aspirin alone, P = 0.07).34
The COMMIT (Clopidogrel and Metoprolol in   Myocardial 
Infarction Trial)35 and the CLARITY (Clopidogrel as Adjunc-
tive Reperfusion Therapy-Thrombolysis in Myocardial 
Infarction)36 trial demonstrated the benefit of dual antiplatelet 
therapy in patients with STEMI. In COMMIT, a total of 
45,852 patients with STEMI treated with aspirin also received 
either clopidogrel 75 mg or placebo for up to 4 weeks in 
hospital or until discharge.35 The rate of the composite 
endpoint of death, reinfarction, or stroke was significantly 
lower in patients receiving clopidogrel plus aspirin versus 
those receiving aspirin alone (9.2% vs 10.1%, P = 0.002).35 
A significant reduction in all-cause death (coprimary end-
point) was also noted with clopidogrel plus aspirin (7.5% vs 
8.1% with aspirin alone, P = 0.03).35 In CLARITY, a total 
of 3491 patients with STEMI treated with aspirin and fibrin-
olytic therapy were randomized to receive either clopidogrel 
(300 mg loading dose followed by 75 mg/day) or placebo.36 
The incidence of the primary efficacy endpoint (composite of 
an occluded infarct-related artery on angiography or death or 
recurrent MI before angiography) was significantly reduced 
in the clopidogrel plus aspirin group versus aspirin alone 
(15% vs 21.7%, P , 0.001).36
The CAPRIE (Clopidogrel versus Aspirin in Patients 
at Risk of Ischemic Events) trial evaluated the efficacy 
of clopidogrel 75 mg versus aspirin 325 mg in secondary 
prevention of atherothrombotic disease in 19,185 patients 
with prior MI (onset within 35 days before randomiza-
tion), stroke/TIA (onset $1 week and #6 months before 
randomization), or symptomatic PAD.37 The incidence of 
the primary composite endpoint of ischemic stroke, MI, 
and vascular death was 5.3% in the clopidogrel arm and 
5.8% in the aspirin arm, a relative risk reduction of 8.7% 
(P = 0.043).37 More recently, the CHARISMA (Clopidogrel 
for High Atherothrombotic Risk and Ischemic Stabiliza-
tion, Management, and Avoidance) trial included 15,603 
patients with either clinically documented atherothrombotic 
disease or multiple risk factors but without documented 
atherothrombotic disease.38 Patients enrolled in CHARISMA 
received either clopidogrel (75 mg/day) plus low-dose aspirin 
(75–162 mg daily) or placebo plus low-dose aspirin for a 
median of 28 months. There was no significant difference 
in the rate of the primary efficacy endpoint (MI, stroke, or 
cardiovascular death) between the two treatment groups 
(6.8% in the clopidogrel plus aspirin group and 7.3% in the 
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aspirin alone group, P = 0.22).38 Treatment with   clopidogrel 
plus aspirin led to a nonsignificant increase in rates of 
severe bleeding (1.7% vs 1.3%, P = 0.09) and fatal bleeding 
(0.3% vs 0.2%; P = 0.17).38 Prespecified subgroup analyses 
revealed that patients with established atherothrombotic dis-
ease (N = 12,153) had a significant reduction in the primary 
endpoint following treatment with clopidogrel plus aspirin 
versus aspirin (6.9% vs 7.9%, P = 0.046), whereas patients 
with multiple risk factors alone (N = 3284) experienced a 
nonsignificant increase in the rate of primary endpoint with 
dual antiplatelet therapy (6.6% vs 5.5% with aspirin alone, 
P = 0.20).38 Additionally, in a post hoc subgroup analysis of the 
CHARISMA trial, patients with documented prior MI, isch-
emic stroke, or symptomatic PAD (N = 9478), also known as 
the “CAPRIE-like” cohort, had significantly lower rates 
of cardiovascular death, MI, or stroke when receiving 
clopidogrel plus aspirin than when treated with placebo 
plus aspirin (7.3% vs 8.8%, respectively; P = 0.01).39 How-
ever, moderate bleeding in the “CAPRIE-like” cohort of 
CHARISMA was significantly higher in the clopidogrel 
plus aspirin group versus the placebo plus aspirin group 
(2.0% vs 1.3%, P = 0.004).39
The CURRENT-OASIS 7 (Clopidogrel Optimal Loading 
Dose Usage to Reduce Recurrent Events/Optimal Antiplate-
let Strategy for Interventions) trial evaluated the effect of 
standard (300 mg loading dose plus 75 mg once daily [qd] 
maintenance dose) and higher-dosing regimens (600 mg 
loading dose plus 150 mg qd maintenance dose for 7 days 
followed by 75 mg qd maintenance dose) of clopidogrel and 
aspirin (high-dose regimen of 300–325 mg qd and standard-
dose regimen of 75–100 mg qd) on cardiovascular outcomes 
and bleeding complications in 25,087 patients with ACS 
with planned early (,24 hours) invasive management with 
intended PCI.40 No significant difference in incidence of 
the primary composite endpoint of cardiovascular death, 
MI, or stroke at Day 30 was observed in the overall patient 
population between the two clopidogrel treatment arms 
(4.4% standard-dose clopidogrel vs 4.2% high-dose clopi-
dogrel; P = 0.370).41 However, treatment with high-dose 
clopidogrel resulted in a significant reduction in incidence 
of cardiovascular events versus standard-dose clopidogrel 
in patients who underwent PCI (3.9% vs 4.5%, P = 0.036), 
with a significant reduction in incidence of MI (2.0% vs 
2.6%, P = 0.012).42 Treatment with high-dose clopidogrel 
was also associated with a significant 42% relative reduc-
tion in the rate of stent thrombosis at Day 30 (definite stent 
thrombosis confirmed by angiography) versus standard-dose 
clopidogrel (hazard ratio [HR] 0.58; P = 0.001).41 In patients 
undergoing PCI, treatment with high-dose clopidogrel was 
associated with a significantly higher rate of CURRENT-
defined major bleeding (1.6% vs 1.1% with standard-dose 
clopidogrel; P = 0.009),   CURRENT-defined severe bleeding 
(1.1% vs 0.8%, respectively; P = 0.06), and red blood cell 
transfusion of two or more units (1.3% vs 0.9%, respec-
tively; P = 0.019).42 Although no significant difference in 
the incidence of cardiovascular outcomes was observed in 
the overall patient population between the two aspirin treat-
ment groups, a significant interaction between high-dose 
versus standard-dose aspirin and high-dose clopidogrel was 
observed, with significant reduction in incidence of cardio-
vascular death, MI, or stroke in patients administered aspirin 
at 300–325 mg qd (3.8% vs 4.6%, P = 0.036).41
New P2Y12 inhibitors
Prasugrel
Prasugrel, a novel thienopyridine inhibitor of the platelet 
P2Y12 ADP receptor, exhibits faster and more potent plate-
let inhibition than clopidogrel.43,44 The clinical efficacy and 
safety of prasugrel was evaluated in the TRITON (Trial to 
Assess Improvement in Therapeutic Outcomes by Optimiz-
ing Platelet Inhibition with Prasugrel).9 TRITON compared 
the clinical efficacy and safety of aspirin plus prasugrel 
(60 mg loading dose and 10 mg daily maintenance dose) 
versus aspirin plus clopidogrel (300 mg loading dose and 
75 mg daily maintenance dose) in 13,608 patients with 
  moderate- to high-risk ACS scheduled for PCI after diag-
nostic   angiography.9 The primary endpoint (cardiovascular 
death, nonfatal MI, or nonfatal stroke) was significantly less 
common with prasugrel plus aspirin than with clopidogrel 
plus aspirin (9.9% vs 12.1%, respectively; P , 0.001).9 
However, the rates of bleeding were significantly higher with 
aspirin plus prasugrel (major bleeding: 2.4% vs 1.8% with 
aspirin plus clopidogrel, P = 0.03; life-threatening bleed-
ing: 1.4% vs 0.9%, respectively; P = 0.01; and fatal bleed-
ing: 0.4% vs 0.1%, respectively; P = 0.002).9 Additionally, 
transfusions were required significantly more often in patients 
receiving aspirin plus prasugrel (4% vs 3% with aspirin plus 
clopidogrel, P , 0.001).9 In patients undergoing coronary 
artery bypass grafting (CABG; N = 368), the incidence of   
TIMI (thrombolysis in myocardial infarction) major bleed-
ing was more than four-fold higher in patients receiving 
aspirin plus prasugrel compared with patients receiving 
aspirin plus clopidogrel (13.4% vs 3.2%, P , 0.001).9 The 
observed increase in bleeding events prompted several post 
hoc analyses to determine the net clinical effect of aspirin 
plus prasugrel in various patient subgroups. Patients with 
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stroke or TIA had a net clinical harm from aspirin plus pra-
sugrel (HR 1.54, P = 0.04), whereas patients $75 years of 
age and those weighing ,60 kg experienced no net benefit 
from aspirin plus prasugrel.9 In patients with STEMI, on the 
other hand, therapy with aspirin plus prasugrel was associated 
with a significant net clinical benefit, without excess bleed-
ing risk.45 Additionally, treatment with aspirin plus prasugrel 
demonstrated significant clinical benefit in patients with 
diabetes46 and in patients who received at least one stent.47 
Taking into account the variable net clinical effect and risks 
of aspirin plus prasugrel in different patient groups, careful 
assessment of patient characteristics is essential prior to 
initiation of therapy.
Ticagrelor (AZD6140)
Ticagrelor (AstraZeneca), a novel nonthienopyridine, 
direct-acting (not a prodrug) oral inhibitor of the P2Y12 
ADP receptor, is characterized by a rapid onset of action 
(2 hours to peak platelet inhibition) and a relatively rapid 
(12 hours) reversal of platelet inhibition.48 Ticagrelor has 
demonstrated greater potency and consistency of plate-
let inhibition compared with clopidogrel.49 The efficacy 
and safety of ticagrelor in combination with aspirin was 
evaluated in the phase 3 PLATO (Platelet Inhibition and 
Clinical Outcomes) trial in patients with ACS, with or 
without ST segment elevation.50 Patients (N = 18,624) 
were randomized to ticagrelor (administered as a 180 mg 
loading dose plus 90 mg twice daily) plus aspirin or 
clopidogrel (300–600 mg loading dose plus 75 mg qd) 
plus aspirin. The primary endpoint was a composite of 
death from vascular causes, MI, or stroke. Treatment with 
ticagrelor led to a significant reduction in the incidence 
of the composite endpoint versus clopidogrel (9.8% vs 
11.7%; P , 0.001). Importantly, ticagrelor demonstrated a 
significant reduction in mortality from any cause (4.5% vs 
5.9%; P , 0.001) after 1 year, with no significant dif-
ferences in rate of major bleeding, defined according to 
trial-specific or TIMI criteria.50 The ticagrelor treatment 
group did show a significantly higher rate of non-CABG-
related major bleeding whether defined according to 
study-specific criteria (4.5% vs 3.8%, P = 0.03) or TIMI 
criteria (2.8% vs 2.2%, P = 0.03).50 Ticagrelor was also 
associated with significantly higher rates of other adverse 
events versus clopidogrel, including dyspnea (13.8% vs 
7.8%, P , 0.001), increase in serum uric acid from baseline 
(15% vs 7%, P , 0.001), and increase in serum creatinine 
from baseline (11% vs 9%, P , 0.001). Phase 3 trials with 
another novel, intravenous P2Y12 ADP receptor antagonist, 
cangrelor, have been terminated due to lack of efficacy 
versus clopidogrel in interim data analyses.51
Elinogrel (PRT060128)
Elinogrel (Portola/Novartis) is a novel nonthienopyridine, 
direct-acting, reversible, and competitive inhibitor of the 
P2Y12 ADP receptor that can be administered orally or 
intravenously.52 Elinogrel is not metabolized by hepatic cyto-
chrome P (CYP)450 enzymes and is characterized by immedi-
ate and near maximal platelet inhibition following intravenous 
administration with a half-life of 12 hours.52,53 The efficacy 
and safety of elinogrel was evaluated versus clopidogrel in 
the phase 2 INNOVATE-PCI trial in patients undergoing 
nonurgent PCI.53 Patients (N = 652) were randomized to 
clopidogrel administered as a 300–600 mg loading dose plus 
75 mg daily after PCI (N = 208), elinogrel administered as a 
120 mg intravenous bolus and 100 mg oral dose plus 100 mg 
twice daily orally after PCI (N = 201), or elinogrel admin-
istered as a 120 mg intravenous bolus and 150 mg oral dose 
plus 150 mg twice daily orally after PCI (N = 207).53
The rates of TIMI major or TIMI minor bleeding in the 
elinogrel and clopidogrel treatment groups were similar 
at both the 24-hour and 120-day timepoints.53 Compared 
with therapy with clopidogrel, treatment with elinogrel 
was associated with a dose-dependent increase in rate of 
bleeding requiring medical attention, mostly occurring at 
the vascular access site during the periprocedural period, 
a higher rate of dyspnea, and a higher rate of transami-
nase elevation.53 Treatment with elinogrel was associated 
with a rate of the composite ischemic endpoint that was 
comparable with that observed with clopidogrel at both 
24 hours and 120 days; the degree of inhibition of peak 
platelet aggregation induced by 5 µM ADP, however, was 
significantly greater with both elinogrel regimens at both 
24 hours and 30 days.53 Furthermore, there were no differ-
ences in periprocedural rates of troponin elevation between 
the elinogrel and clopidogrel treatment groups.53 Initiation 
of a phase 3 program designed to evaluate the efficacy and 
safety of elinogrel in patients with chronic coronary heart 
disease is anticipated in 2011.
Although prasugrel, ticagrelor, and elinogrel have all 
demonstrated more potent platelet inhibition than clopi-
dogrel, these agents target only the P2Y12 ADP receptor and 
do not significantly inhibit other platelet activation pathways. 
Therefore, even in the presence of these agents, other platelet 
activation pathways, including the PAR-1 pathway activated 
by thrombin, remain functional, allowing continued platelet 
aggregation and thrombosis.
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Limitations of current antiplatelet therapy
Residual risk for thrombotic/ischemic events
Despite receiving dual antiplatelet therapy with aspirin and a 
P2Y12 inhibitor, a considerable number of patients continue to 
experience recurrent thrombotic events (Figure 2).8–10,50 For 
example, the CURE trial demonstrated a 20% risk reduction 
in cardiovascular death, nonfatal MI, and nonfatal stroke 
in patients receiving clopidogrel plus aspirin versus aspirin 
alone, but the risk for an ischemic event at 12 months in 
patients receiving clopidogrel plus aspirin was still substan-
tial (9.3%).10 Similarly, in TRITON and PLATO, the most 
recent large trials of antiplatelet therapy in patients with ACS, 
approximately 10% of patients receiving dual antiplatelet 
therapy experienced cardiovascular death, MI, or stroke.9,50 
As discussed previously, dual antiplatelet therapy with 
aspirin and clopidogrel did not provide a significant clinical 
benefit versus aspirin alone in the overall population of the 
CHARISMA trial, and even among the cohort of patients 
with prior MI, stroke, or PAD, in whom a significant clini-
cal benefit versus aspirin alone was observed, over 7% of 
patients receiving clopidogrel plus aspirin experienced an 
ischemic event.39 Thus, a considerable number of patients 
remain at residual risk for thrombotic events after both acute 
and longer-term treatment with dual antiplatelet therapy.
Residual risk of ischemic events with aspirin and a P2Y12 
inhibitor has been attributed to the fact that although multiple 
pathways contribute to platelet activation, these agents do 
not inhibit pathways other than those stimulated by TxA2 
and ADP, respectively.6 TxA2 and ADP are involved in initial 
platelet recruitment and adhesion during both hemostasis and 
thrombosis. Other platelet activation pathways, including 
the PAR-1 pathway activated by thrombin (the most potent 
platelet activator), remain active in the presence of current 
antiplatelet agents. The lack of an inhibitory effect of current 
therapies on multiple platelet activation pathways allows for 
continued platelet reactivity in the presence of potent ago-
nists, such as thrombin (Figure 1B), thereby increasing the 
risk for recurrent thrombotic events, including death. New 
therapies that target pathways that are not affected by aspirin 
or P2Y12 inhibitors could provide complementary and more 
comprehensive inhibition of platelet activation, and thereby 
contribute to greater inhibition of platelet-mediated throm-
bosis, when used in combination with the current standard-
of-care therapies. Importantly, preclinical evidence suggests 
that the principal thrombin receptor on platelets is critical for 
uncontrolled thrombus growth and propagation into the arte-
rial lumen, but it is not required for initial platelet deposition 
that may help facilitate vascular repair and does not inter-
fere with thrombin-mediated conversion of fibrinogen 
into fibrin. Mice with genetic inactivation of the primary 
thrombin receptor exhibit markedly reduced platelet accu-
mulation and thrombus growth but have normal initial 
platelet deposition and fibrin accumulation, and they do 
not bleed   spontaneously.54 Thus, inhibition of PAR-1 could 
potentially reduce the risk of thrombosis without excess 
bleeding risk.
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Bleeding risk
Increased bleeding risk is another significant clinical limita-
tion of current oral antiplatelet therapies. Aspirin has been 
associated with a dose-dependent increase in bleeding risk, 
particularly gastrointestinal bleeding,55,56 even at low   doses.55 
The addition of clopidogrel to aspirin has been shown to 
further increase the risk of bleeding, as well as the need for 
transfusions.10,33,34,57 In an analysis from the CURE trial, the 
incidence of major bleeding increased significantly with higher 
aspirin doses (#100 mg, 101–199 mg, and $200 mg) in both 
the clopidogrel plus aspirin and the aspirin monotherapy arms, 
indicating a dose-dependent effect of aspirin on bleeding 
risk.57 In CHARISMA, the rate of severe bleeding was 1.7% 
in the clopidogrel plus aspirin group versus 1.3% in the aspi-
rin group (P = 0.09), and the rate of moderate bleeding was 
2.1% with clopidogrel plus aspirin versus 1.3% with aspirin 
(P , 0.001).38 In TRITON, the combination of aspirin and pra-
sugrel was associated with a significantly greater risk of TIMI 
major, life-threatening, fatal, and CABG-related bleeding, as 
well as a significantly higher rate of transfusions than aspirin 
plus clopidogrel.9 Increased bleeding risk with prasugrel is 
most likely related to its greater inhibitory effect on ADP-
induced platelet aggregation compared with clopidogrel.
Increased bleeding risk with aspirin and the combination 
of aspirin plus an ADP receptor inhibitor has been attributed 
to the fact that aspirin and P2Y12 inhibitors interfere with the 
TxA2 and ADP platelet activation pathways, which are essential 
for normal hemostasis.3–6,22 These considerations underscore 
the need for novel agents that provide more comprehensive 
platelet inhibition without interfering with platelet activation 
pathways critical for hemostasis, for greater protection against 
thrombotic events and no incremental bleeding risk.
Whereas bleeding and blood transfusions are clearly 
undesirable outcomes on their own, these events have also 
recently been shown to represent independent predictors 
of short- and long-term mortality in patients with athero-
thrombotic disease.58,59 An analysis from four multicenter, 
randomized clinical trials in 26,452 patients with NSTE ACS 
showed a significant increase in unadjusted rates of 30-day 
and 6-month mortality with greater bleeding severity (the 
HRs for 6-month mortality ranged from 1.4 for mild bleed-
ing to 2.1 for moderate bleeding and 7.5 for severe bleeding; 
P , 0.001).59 In a separate study of 24,112 patients with ACS, 
those who underwent blood transfusion had significantly 
higher rates of 30-day mortality (8% vs 3.1%, P , 0.001), 
MI (25.2% vs 8.2%, P , 0.001), and the composite of death 
or MI (29.2% vs 10.0%, P , 0.001) than patients who did 
not require a transfusion.58 Some of the increase in adverse 
outcomes may also be related to the suspension of needed 
antithrombotic therapies.
Variability in response to antiplatelet therapy
Several studies have documented variable responsiveness 
of platelets to therapy with aspirin and/or clopidogrel.32,60–62 
Although a standardized definition and methodology for 
measurement of low responsiveness to antiplatelet therapy 
has not been established, sufficient evidence supports the 
concept that persistence of enhanced platelet reactivity 
despite the use of aspirin61,63 or clopidogrel60,64–66 is clinically 
relevant. For example, Chen et al63 evaluated responsiveness 
to aspirin in 468 patients with stable coronary artery disease 
(CAD) using the point-of-care VerifyNow   Aspirin assay, and 
found that patients with aspirin resistance (defined as aspirin 
reaction unit $550, and observed in 27.4% of patients) were 
at almost three-fold higher risk of cardiovascular death, MI, 
unstable angina requiring hospitalization, stroke, or a TIA 
than aspirin-sensitive patients (15.6% vs 5.3%, respectively; 
P , 0.001). Similarly, a correlation between a low level of 
inhibition of ADP-induced platelet aggregation in response 
to clopidogrel and recurrence of ischemic events has been 
documented in several studies in patients with ACS and those 
undergoing PCI (Figure 3).64–66
Although the mechanisms responsible for the variability and 
low responsiveness to aspirin and clopidogrel have not been fully 
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32%; fourth: .32%) in 802 patients undergoing elective PCI and receiving clopidogrel 
600 mg loading dose. 
Reprinted from the Journal of the American College of Cardiology, 48, Hochholzer w, 
Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Büttner 
HJ, Neumann FJ. Impact of the Degree of Peri-Interventional Platelet Inhibition After 
Loading with Clopidogrel on Early Clinical Outcome of Elective Coronary Stent 
Placement, 1742–1750, Copyright 2006, with permission from Elsevier.65
Abbreviations: ADP, adenosine diphosphate; MACE, major adverse cardiac events; 
PCI, percutaneous coronary intervention.
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elucidated, recent analyses suggest that genetic polymorphisms 
of the CYP450 enzymes can significantly modulate individual 
response to clopidogrel and are important determinants of 
prognosis.67–69 Clopidogrel is a prodrug that is converted to an 
active metabolite by CYP enzymes.48 A recent study of patients 
with acute MI treated with clopidogrel demonstrated that the 
carriers of the CYP2C19*2 allelic variant (CYP2C19) had a sig-
nificantly higher rate of ischemic events (death, nonfatal MI, or 
urgent revascularization) than the noncarriers (10.9 events per 
100 patient-years vs 2.9 events per 100 patient-years, respec-
tively; adjusted HR 5.38, P , 0.0001).67 Similarly, in a French 
registry of patients with acute MI treated with clopidogrel, those 
patients who had any two loss-of-function CYP2C19 variants 
had a significantly higher rate of death, nonfatal MI, or stroke 
(21.5% vs 13.3% in patients with none of the loss-of-function 
alleles, adjusted HR 1.98); the increased risk was particularly 
prominent among patients undergoing PCI.69 Additionally, in 
TRITON, patients treated with clopidogrel who were carriers 
of one or more reduced-function CYP2C19 alleles had a sig-
nificantly higher rate of cardiovascular events than noncarriers 
(12.1% vs 8.0%, respectively; P = 0.01);68 this finding was not 
observed in patients treated with   prasugrel.   Clopidogrel has 
also demonstrated potential for interaction with other drugs 
metabolized by P450 enzymes, such as proton pump inhibitors, 
and this interaction can significantly reduce the peak plasma 
  concentrations of the active metabolite of clopidogrel and 
diminish its platelet-inhibitory effects.70,71 A trial of clopidogrel 
with or without omeprazole in CAD demonstrated no evidence 
of an adverse cardiovascular interaction between omeprazole 
and clopidogrel.72
In summary, despite the proven clinical benefits of current 
oral antiplatelet agents, they are associated with significant 
residual risk for ischemic events, increased bleeding risk, and 
variable patient responsiveness, underscoring the need for 
novel antiplatelet agents that can provide further reductions 
in ischemic events without increased bleeding liability.
PAR-1/thrombin receptor antagonists 
(TRAs): a novel class of oral  
antiplatelet agents
The platelet PAR-1 receptor is an important mediator of plate-
let activation that contributes to thrombosis but may not be 
essential for hemostasis. Importantly, current oral antiplatelet 
agents do not inhibit the thrombin-PAR-1 platelet activation 
pathway, and novel oral antiplatelet agents targeting the 
PAR-1 pathway may provide more comprehensive platelet 
inhibition and incremental clinical benefits, potentially 
without increased bleeding risk. Therefore, inhibition of 
PAR-1 represents a rational approach to development of novel 
antiplatelet agents, and two oral PAR-1 inhibitors are cur-
rently in advanced clinical development: Atopaxar (E5555) 
(Eisai) is currently being evaluated in phase 2 trials, whereas 
vorapaxar (SCH530348) (Merck) is undergoing evaluation 
in two large phase 3 trials.
Atopaxar (E5555)
Atopaxar is a PAR-1 antagonist that has demonstrated potent 
inhibition of thrombin receptor agonist peptide (TRAP)-
induced platelet aggregation in preclinical studies,73 as well 
as the inhibition of thrombin-stimulated release of soluble 
CD40 ligand (sCD40L) and interleukin 6 (IL-6), and the 
expression of P-selectin on human endothelial cells.74
The safety and efficacy of atopaxar has been evaluated 
in two phase 2 trials (J-LANCELOT) in Japanese patients 
with ACS (N = 241) or high-risk CAD (N = 263).75 Patients 
were allocated to atopaxar plus standard therapy or placebo 
plus standard therapy.75 Treatment with atopaxar was associ-
ated with similar rates of TIMI-defined major, minor, and 
minimal bleeds requiring medical attention versus treatment 
with placebo in patients with ACS (5.0% with atopaxar [all 
doses] vs 6.6% with placebo), as well as in patients with CAD 
(1.5% in both the atopaxar [all doses] and placebo groups).75 
Treatment with atopaxar led to numerically lower rates of 
major adverse cardiac events versus placebo in patients with 
ACS (5.0% vs 6.6%, respectively; P = 0.73) and in patients 
with CAD (1.0% vs 4.5%, respectively; P = 0.066).75 There 
were no significant differences in rates of adverse events or 
serious adverse events between the atopaxar and placebo 
treatment groups in either patient population.75 Treatment 
with atopaxar led to higher prevalence of hepatic enzyme 
elevation versus treatment with placebo in patients with 
ACS (23.3% vs 11.5%, respectively; P = 0.064), as well as 
in patients with CAD (10.2% vs 1.5%; P = 0.032).75 A trend 
toward dose-dependent QTcF prolongation with atopaxar 
was observed in patients with ACS (P = 0.074), and a sig-
nificant, dose-dependent prolongation of QTcF interval with 
atopaxar was reported in patients with CAD (P = 0.026).75
The LANCELOT ACS trial evaluated safety and efficacy 
of atopaxar in combination with aspirin and clopidogrel or 
ticlopidine versus placebo plus aspirin and clopidogrel or 
ticlopidine in patients with NSTE ACS (N = 603).76   Treatment 
with atopaxar was associated with similar rates of any 
CURE-defined bleeding (3.1% with atopaxar vs 2.2% with 
placebo; P = 0.63) and any TIMI-defined bleeding (9.3% with 
atopaxar vs 10.1% with placebo; P = 0.77).76 Similar rates 
of cardiovascular death, MI, stroke, or recurrent ischemia 
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were observed between the atopaxar (N = 461) and placebo 
(N = 142) groups (8.0% vs 7.8% with placebo; P = 0.93).76 
However, a trend toward lower incidence of cardiovascular 
death, MI, or stroke was observed in patients treated with ato-
paxar versus placebo (3.3% vs 5.6%; P = 0.20).76 A significant, 
33% relative reduction in the incidence of Holter-detected 
ischemia was observed at 48 hours postdosing in patients 
receiving atopaxar (18.7% vs 28.1% with placebo; P = 0.02).76 
Treatment with atopaxar led to a dose-dependent elevation in 
liver function enzymes, and the highest maintenance doses 
(100 mg and 200 mg) of atopaxar were associated with signifi-
cant prolongation of QTc interval versus placebo (P , 0.05 
for each comparison).76 The elevations in liver enzymes and 
QTc interval prolongations seen in LANCELOT were also 
apparent in the J-LANCELOT study discussed previously but 
were not reported in the phase 2 trials with a PAR-1 antagonist 
vorapaxar (discussed in the following section).
Vorapaxar (SCH530348)
Vorapaxar, an orally bioavailable PAR-1 antagonist, is a potent 
and selective inhibitor of thrombin-induced platelet aggrega-
tion that does not interfere with clotting parameters (such as 
prothrombin time).77 The phase 2 TRA-PCI (Thrombin Recep-
tor Antagonist-Percutaneous Coronary   Intervention) trial 
evaluated the safety and efficacy of   vorapaxar (administered 
as either a 10 mg, 20 mg, or 40 mg loading dose on Day 1, fol-
lowed by a maintenance dose of 0.5 mg qd, 1 mg qd, or 2.5 mg 
qd for 59 days) used in combination with standard oral anti-
platelet therapy (aspirin and clopidogrel) and an antithrombin 
agent (heparin or bivalirudin) in patients in whom nonurgent 
PCI was planned.78 In patients who actually underwent PCI 
(primary cohort), there was no significant difference in the 
incidence of TIMI major bleeding and minor bleeding among 
patients receiving the standard-of-care therapy plus vorapaxar 
(all doses) versus standard-of-care therapy alone (2.8% and 
3.3%, respectively; P = NS).78 Although the trial was not 
powered to detect a difference in clinical endpoints, the inci-
dence of death or major adverse cardiac events at 60 days 
was reduced from 8.6% in the standard-of-care alone therapy 
group to 5.7% in the group receiving vorapaxar plus standard 
of care due to a reduced rate of MI, although this difference did 
not achieve statistical significance.78 A pharmacodynamic sub-
study of TRA-PCI demonstrated that the complete ($80%) 
inhibition of TRAP-induced platelet aggregation is achieved 
most rapidly and most consistently with the 40 mg loading 
dose of vorapaxar, and that the maintenance doses of 1.0 mg 
qd and 2.5 mg qd sustained complete inhibition at 30 days and 
60 days.78 A separate pharmacodynamic study demonstrated 
that in the absence of the loading dose, the 2.5 mg qd main-
tenance dose provides the complete ($80%) inhibition of 
TRAP-induced platelet aggregation more consistently than 
the 1.0 mg qd maintenance dose.79 Of note, vorapaxar did not 
interfere with platelet aggregation induced by other agonists 
(eg, ADP, arachidonic acid, or collagen),80 demonstrating that 
it is a specific PAR-1 inhibitor that does not inhibit platelet 
activation pathways required for hemostasis. The safety and 
efficacy of oral vorapaxar were also documented in a phase 2 
trial in Japanese patients with NSTE ACS in whom PCI was 
planned.81 In this study, the incidence of TIMI major or minor 
bleeding in patients receiving vorapaxar plus the standard-of-
care therapy (aspirin, ticlopidine, and heparin) was similar 
to the rate observed with the standard-of-care therapy alone, 
whereas the incidence of nonfatal MI was significantly lower 
in the vorapaxar group (all doses: 16.9% vs 42.9% in the 
control group, P = 0.013).81 Furthermore, in a phase 2 trial in 
Japanese subjects with prior ischemic stroke, the addition of 
vorapaxar to aspirin was not associated with any episodes of 
TIMI major, TIMI minor, or non-TIMI bleeding.82 These results 
collectively suggest that the addition of vorapaxar to standard 
therapy may provide incremental reductions in ischemic 
events. This hypothesis is currently being evaluated in two large 
phase 3 trials, one in patients presenting with NSTE ACS,83 
and the other in secondary prevention in patients with a his-
tory of prior MI, ischemic stroke, or symptomatic PAD.84 
The trial in patients presenting with NSTE ACS has com-
pleted enrollment. The prespecified number of primary and 
secondary efficacy events has been reached, and the results 
were expected to be presented in the second half of 2011. 
It should be noted, though, that although the trial had reached 
the prespecified number of primary and secondary events, 
it was stopped prematurely by the Data Safety Monitoring 
Board in January 2011 for undisclosed reasons. As a result, 
not all patients in this trial will have a prespecified minimum 
of 1-year follow-up. In the secondary prevention trial, study 
drug therapy has been discontinued among patients with prior 
ischemic stroke and those who had a stroke during the study as 
of January 2011,85 at the recommendation of the Data Safety 
Monitoring Board, due to increased incidence of intracranial 
hemorrhage in the vorapaxar arm that was not outweighed 
by considerations of potential ischemic benefit. Study drug 
therapy in the secondary prevention trial is being continued 
in patients with prior MI and those with symptomatic PAD.
Conclusion
Current oral antiplatelet agents, namely aspirin and P2Y12 
ADP receptor inhibitors, have demonstrated clinical benefits 
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in a wide range of patients with atherothrombotic disease. 
However, these agents are associated with important clinical 
limitations, such as the high residual risk for ischemic events, 
increased risk of bleeding, and variable responsiveness or 
resistance. Significant residual risk for ischemic events exists 
because aspirin and P2Y12 ADP receptor inhibitors inhibit 
platelet activation pathways stimulated by TxA2 and ADP but 
do not affect additional platelet activation pathways contrib-
uting to thrombosis. This lack of comprehensive inhibition 
of platelet-mediated thrombosis, including the absence of 
inhibition of PAR-1-mediated platelet activation induced 
by thrombin, effectively exposes patients to a residual risk 
for thrombotic events. The increased risk of bleeding with 
aspirin and P2Y12 ADP receptor inhibitors can be explained 
by their interference with TxA2 and ADP platelet activation 
pathways, which are critical for normal hemostasis. Reduced 
responsiveness or resistance to aspirin and clopidogrel, the 
causes of which remain to be fully elucidated, has been 
shown to be associated with increased risk for poor clinical 
outcomes. Taken together, these limitations of current anti-
platelet agents underscore the need for agents with a novel 
mechanism of action that may provide more comprehen-
sive platelet inhibition for further reductions in morbidity 
and mortality in patients with atherothrombotic disease. 
Oral PAR-1 antagonists are a promising new class of 
  antiplatelet agents, and the first agent in this class, vorapaxar, 
is currently being evaluated in two large phase 3 trials.
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